The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis

The British Journal of Dermatology
P C van de KerkhofJ Revuz

Abstract

Our purpose was to find out whether the addition of calcipotriol ointment (50 micrograms/g) to systemic treatment with acitretin produces additional therapeutic effects and thereby an acitretin-sparing effect, and further to investigate the safety and tolerability of this combination. A multicentre, randomized, double-blind placebo-controlled study was designed. Patients were randomized to receive calcipotriol or placebo. All patients were treated with a starting dose of 20 mg acitretin per day and doses were adjusted at 2-weekly intervals with increments of 10 mg per day up to a maximum of 70 mg per day. The dose requirement for acitretin, clinical signs and adverse events were recorded. Seventy-six patients were randomized to treatment with calcipotriol 50 micrograms/g ointment twice daily and 59 patients to treatment with the vehicle only twice daily. Clearance or marked improvement was achieved by 67% of the patients in the calcipotriol group and by 41% of the patients in the placebo group (P = 0.006). Calcipotriol treatment proved to have a statistically significant additional effect to acitretin on the Psoriasis Area and Severity Index, redness, thickness and scaliness as compared with placebo. Clearance or marked improve...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Dec 1, 1992·Journal of the American Academy of Dermatology·J H Saurat
May 1, 1992·Journal of the American Academy of Dermatology·W J CunliffeJ P Ortonne
Sep 1, 1988·Journal of the American Academy of Dermatology·H GollnickE Hoting
Aug 1, 1988·The British Journal of Dermatology·K KragballeH Søgaard
Jan 1, 1994·Dermatology : International Journal for Clinical and Investigative Dermatology·C A RamsayE Wegmann
May 1, 1994·The American Journal of Physiology·J Chentoufi, P J Marie
Feb 18, 1993·Nature·C CarlbergW Hunziker

❮ Previous
Next ❯

Citations

May 15, 2007·Archives of Dermatological Research·A NastB Rzany
Feb 22, 2012·Archives of Dermatological Research·A NastUNKNOWN Berufsverband Deutscher Dermatologen
Jul 1, 2005·Journal of Cutaneous Medicine and Surgery·Judy HuSteven R Feldman
Jan 19, 2013·American Journal of Clinical Dermatology·Cheryl J GustafsonSteven R Feldman
Feb 28, 2004·Journal of the American Academy of Dermatology·Mark LebwohlSteven R Feldman
Oct 6, 1997·Clinics in Dermatology·P C van de Kerkhof
Jun 26, 2001·Clinical and Experimental Dermatology·P C van de Kerkhof
Aug 5, 1998·Current Opinion in Nephrology and Hypertension·A VerstuyfC Mathieu
Nov 24, 1999·Journal of the European Academy of Dermatology and Venereology : JEADV·A GiannettiM Cespa
Mar 24, 2010·International Journal of Nanomedicine·Yin-Ku LinJia-You Fang
Apr 30, 2002·American Journal of Clinical Dermatology·Jennifer Cather, Alan Menter
Jun 20, 2003·American Journal of Clinical Dermatology·Jong Hyun RimJai Il Youn
Jul 17, 2014·American Journal of Clinical Dermatology·J Daniel JensenNaveed Sami
Nov 22, 2014·Dermatologic Clinics·John B KellyBruce E Strober
Aug 10, 2005·Expert Opinion on Pharmacotherapy·Chai Sue Lee, John Koo
Jul 16, 2008·Expert Opinion on Drug Metabolism & Toxicology·Mei-Lin PangJohn Koo
Feb 16, 2005·Expert Opinion on Drug Safety·JoEllen Van Zander, Seth J Orlow
Jul 1, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·P C M van de Kerkhof, K Kragballe
Dec 26, 2006·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Alexander NastUNKNOWN Germany Society for Dermatology
Jul 11, 2007·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Alexander NastUNKNOWN Berufsverband Deutscher Dermatologen (BVDD)
Dec 18, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·P C M van de KerkhofK Papp
Nov 4, 2000·Expert Opinion on Investigational Drugs·A VerstuyfC Mathieu
Jul 7, 2015·Indian Journal of Dermatology, Venereology and Leprology·Bhawna WadhwaVijay Kumar Garg
Sep 29, 2004·Dermatologic Clinics·David S Aaronson, Mark Lebwohl
May 10, 2017·The Journal of Dermatological Treatment·Karina KooTina Bhutani
Sep 4, 2015·Journal of Cutaneous Medicine and Surgery·Melinda J GooderhamKim A Papp
Sep 28, 2017·Journal of Cutaneous Medicine and Surgery·Lyn C GuentherCatherine Zip
Sep 25, 2018·International Journal of Dermatology·Shivani B Kaushik, Mark G Lebwohl
Aug 29, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·D PathiranaB Rzany
Apr 29, 2010·The British Journal of Dermatology·A D OrmerodUNKNOWN BAD Clinical Standards Unit
Aug 30, 2008·The British Journal of Dermatology·A P TownshendH C Williams
Sep 28, 2010·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Silja Domm, Ulrich Mrowietz
Apr 12, 2012·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Alexander NastUNKNOWN Berufsverband Deutscher Dermatologen (BVDD)
Dec 10, 2009·Expert Opinion on Drug Safety·Chai Sue Lee, Kai Li
Aug 15, 2001·The British Journal of Dermatology·S Lamba, M Lebwohl
Mar 17, 2011·Journal of the European Academy of Dermatology and Venereology : JEADV·E SbidianH Bachelez
Mar 6, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·R G Langley
Apr 27, 2002·Journal of Cutaneous Medicine and Surgery·Jean-François Tremblay, Robert Bissonnette
Jul 31, 2007·Lancet·Alan Menter, Christopher Em Griffiths
Aug 30, 2008·Clinics in Dermatology·Richard B Warren, Christopher E M Griffiths
Jul 31, 2013·Actas dermo-sifiliográficas·G CarreteroUNKNOWN Psoriasis Group of the AEDV

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.